AstraZeneca (AZN) Given a GBX 6,470 Price Target at Kepler Capital Markets

Kepler Capital Markets set a GBX 6,470 ($84.54) price target on AstraZeneca (LON:AZN) in a report published on Monday, Borsen Zeitung reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other analysts also recently commented on AZN. Goldman Sachs Group set a GBX 5,000 ($65.33) target price on AstraZeneca and gave the company a sell rating in a research note on Monday. UBS Group reiterated a sell rating and set a GBX 5,400 ($70.56) target price on shares of AstraZeneca in a research note on Tuesday, May 7th. Deutsche Bank reiterated a buy rating and set a GBX 6,800 ($88.85) target price (down from GBX 6,900 ($90.16)) on shares of AstraZeneca in a research note on Friday, May 10th. Bryan, Garnier & Co reiterated a neutral rating on shares of AstraZeneca in a research note on Friday, March 29th. Finally, Jefferies Financial Group reiterated a hold rating and set a GBX 6,400 ($83.63) target price on shares of AstraZeneca in a research note on Friday, March 29th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of GBX 6,397.70 ($83.60).

AstraZeneca stock opened at GBX 5,813.98 ($75.97) on Monday. The company has a current ratio of 0.75, a quick ratio of 0.57 and a debt-to-equity ratio of 179.66. AstraZeneca has a twelve month low of GBX 5,110 ($66.77) and a twelve month high of GBX 6,540 ($85.46). The company has a market capitalization of $76.36 billion and a P/E ratio of 30.60.

In other news, insider Marc Dunoyer purchased 8,500 shares of the stock in a transaction dated Tuesday, May 7th. The shares were purchased at an average cost of GBX 5,800 ($75.79) per share, with a total value of £493,000 ($644,191.82). Also, insider Philip A. J. Broadley purchased 520 shares of the stock in a transaction dated Tuesday, April 30th. The shares were purchased at an average cost of GBX 5,738 ($74.98) per share, for a total transaction of £29,837.60 ($38,988.11).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: How are dividend achievers different from dividend aristocrats?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.